

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

POLL RESULTS OF THE 2021 FIRST EXTRAORDINARY GENERAL MEETING

POLL RESULTS OF THE EGM

The Board hereby announces that the poll results in respect of the special resolution proposed at the EGM on Friday, July 30, 2021. The special resolution was duly passed.

ADJUSTMENT OF BUSINESS SCOPE

In accordance with the poll results of the EGM, the Board is pleased to announce that the business scope of the Company has been adjusted to: “Permitted items: Class III medical device operation; drug production; drug import and export; drug retail; drug wholesale; import and export of goods; technology import and export. (For projects that are subject to approval in accordance with the laws, business activities can only be conducted after obtaining approval(s) from the relevant departments, the actual business projects as approved under the approval documents or license documents granted by the relevant departments shall prevail) General projects: Class I medical device sales; Class II medical device sales; medical research and experimental development; technical services, technology development, technology consulting, technology exchange, technology transfer, technology promotion. (Except for projects subject to approval by the laws, business activities can be conducted independently with the business license in accordance with the laws).”

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In accordance with the poll results of the EGM, the Board is pleased to announce that the Articles of Association has been amended in relation to the business scope and the registration of changes in the register of shareholders.

References are made to the notice (the “**Notice**”) and the circular (the “**Circular**”) of the 2021 first extraordinary general meeting (the “**EGM**”) of CanSino Biologics Inc. (the “**Company**”) both dated July 15, 2021, and the announcement of the Company dated July 29, 2021. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company announces that at its EGM held on Friday, July 30, 2021, the special resolution proposed was duly passed. The EGM was convened by the board (the “**Board**”) of directors of the Company.

Further details of the special resolution are set out in the Notice and the Circular.

ATTENDANCE AT THE EGM

The Board is pleased to announce that the EGM was held at Beijing Hall, 3rd Floor, Beijing Four Seasons Hotel, No. 48 Liangmaqiao Road, Chaoyang District, Beijing, the People's Republic of China, on July 30, 2021.

The attendance of the EGM is as follows:

Class of Shares	Number of Shares in issue (and entitling holders to attend and vote for or against any resolution)	Number of Shares present (in person or by proxy)	Approximate %
H Shares	132,670,900	72,691,192	54.7906
A Shares	114,778,999	51,375,451	44.7603
Total	247,449,899	124,066,643	50.1381

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolution proposed at the EGM as set out in rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolution proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on the special resolution proposed at the EGM.

POLL RESULTS OF THE EGM

The poll results of the EGM were as follows:

Special Resolution ⁽¹⁾	For ⁽³⁾	Against ⁽³⁾	Abstain ⁽³⁾	Passed by Shareholders ⁽²⁾
To consider and approve the proposed adjustment of business scope and proposed amendments to the articles of association of the Company as set out in the Circular.	124,035,527 (99.9749%)	31,116 (0.0251%)	0 (0.0000%)	Yes

Notes:

- (1) Please refer to the Notice and Circular for details of the special resolution.
- (2) A special resolution is passed by more than two-thirds of the votes casted in favor of it.
- (3) All percentages rounded to four decimal places. The percentage figures included in this table have been subject to rounding adjustments.

ADJUSTMENT OF BUSINESS SCOPE

In accordance with the poll results of the EGM, the Board is pleased to announce that, the business scope of the Company has been adjusted to: “Permitted items: Class III medical device operation; drug production; drug import and export; drug retail; drug wholesale; import and export of goods; technology import and export. (For projects that are subject to approval in accordance with the laws, business activities can only be conducted after obtaining approval(s) from the relevant departments, the actual business projects as approved under the approval documents or license documents granted by the relevant departments shall prevail) General projects: Class I medical device sales; Class II medical device sales; medical research and experimental development; technical services, technology development, technology consulting, technology exchange, technology transfer, technology promotion. (Except for projects subject to approval by the laws, business activities can be conducted independently with the business license in accordance with the laws)”.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In accordance with the poll results of the EGM, the Board is pleased to announce that the Articles of Association has been amended in relation to the business scope and the registration of changes in the register of shareholders. For the details of the amendments to the Articles of Association, please refer to the Circular and the announcement of the Company dated June 11, 2021.

SCRUTINEERS

The H share registrar of the Company, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM. Two representatives of the Shareholders, one lawyer of Tian Yuan Law Firm, and one supervisor of the Company participated in the scrutiny of the poll results.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, July 30, 2021

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.